Diamedica Therapeutics Inc. 8-K Filing

FAQ

Filing Documents

• dmtp20251217_8k.htm (8-K) — 33KB
• ex_900450.htm (EX-99.1) — 12KB
• diamedicalogo.jpg (GRAPHIC) — 7KB
• 0001437749-25-038211.txt ( ) — 185KB
• dmac-20251218.xsd (EX-101.SCH) — 3KB
• dmac-20251218_def.xml (EX-101.DEF) — 11KB
• dmac-20251218_lab.xml (EX-101.LAB) — 14KB
• dmac-20251218_pre.xml (EX-101.PRE) — 11KB
• dmtp20251217_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 18, 2025, DiaMedica Therapeutics Inc. provided a DM199 preeclampsia program update following its pre-IND meeting with the United States Food and Drug Administration (FDA). The text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 7.01 and Exhibit 99.1 to this report shall not be deemed to be "filed" with the United States Securities and Exchange Commission for purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be incorporated by reference into any filings made by the DiaMedica under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. As previously announced, DiaMedica requested and completed an in-person pre-IND meeting with the FDA for a planned study evaluating DM199 in pre-eclampsia. Minutes from the meeting have affirmed the FDA's request for one additional non-clinical, 10-day modified embryo-fetal development (EFD) and pre and postnatal Development (PPND) study in a rabbit model. Preparations for this study have commenced and results are expected to be available by the second quarter of 2026. Cautionary Note Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in report, the words "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," or "will," the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this report include statements regarding expectations regarding the timing for a rabbit treatment study and the preeclampsia Phase 2 investigator-sponsored trial; anticipated clinical benefits and success of DM199 for the treatment of preeclampsia and acute ischemic stroke; and future regulatory requirements. Such statements and information reflect management's current view and DiaMedica undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statem

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description Manner of Filing 99.1 Press Release dated December 18, 2025 Furnished Electronically 104 Cover Page Interactive Data File (formatted as inline XBRL) Filed Electronically

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIAMEDICA THERAPEUTICS INC. Date: December 18, 2025 By: /s/ Scott Kellen Scott Kellen Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR